A Phase I Trial Of Andrographolide In HIV Positive Patients And Normal Volunteers
| Effect | Increase |
| Trial Design | Non-controlled trial |
| Trial Length | n/a |
| Number of Subjects | 17 |
| Sex | n/a |
Andrographolide at up to 30mg daily failed to influence the amount of the HIV virus in persons with HIV and increased serum liver enzymes, although it acted to normalize CD4+ T-cells (suppressed in persons with HIV). In a small cohort of persons without HIV, CD4+ T-cells were reduced.
